Last reviewed · How we verify
Carboplatin AUC 5 IVa
Carboplatin AUC 5 IVa is a Platinum-based chemotherapy agent Small molecule drug developed by Gruppo Oncologico Italiano di Ricerca Clinica. It is currently in Phase 2 development for Various solid tumors (Phase 2 investigational).
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cell replication and inducing apoptosis in cancer cells.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cell replication and inducing apoptosis in cancer cells. Used for Various solid tumors (Phase 2 investigational).
At a glance
| Generic name | Carboplatin AUC 5 IVa |
|---|---|
| Sponsor | Gruppo Oncologico Italiano di Ricerca Clinica |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, disrupting DNA synthesis and repair mechanisms. This leads to cell cycle arrest and programmed cell death in rapidly dividing cancer cells. The AUC (Area Under the Curve) dosing of 5 represents a personalized dosing approach based on renal function and other patient factors to optimize efficacy while managing toxicity.
Approved indications
- Various solid tumors (Phase 2 investigational)
Common side effects
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Allergic reactions
Key clinical trials
- A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer (PHASE2)
- A Prospective Single-Arm Study（NCLDR） (EARLY_PHASE1)
- Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer (PHASE3)
- Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
- Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
- A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma (PHASE2)
- Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer (PHASE2)
- A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin AUC 5 IVa CI brief — competitive landscape report
- Carboplatin AUC 5 IVa updates RSS · CI watch RSS
- Gruppo Oncologico Italiano di Ricerca Clinica portfolio CI
Frequently asked questions about Carboplatin AUC 5 IVa
What is Carboplatin AUC 5 IVa?
How does Carboplatin AUC 5 IVa work?
What is Carboplatin AUC 5 IVa used for?
Who makes Carboplatin AUC 5 IVa?
What drug class is Carboplatin AUC 5 IVa in?
What development phase is Carboplatin AUC 5 IVa in?
What are the side effects of Carboplatin AUC 5 IVa?
What does Carboplatin AUC 5 IVa target?
Related
- Drug class: All Platinum-based chemotherapy agent drugs
- Target: All drugs targeting DNA
- Manufacturer: Gruppo Oncologico Italiano di Ricerca Clinica — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various solid tumors (Phase 2 investigational)
- Compare: Carboplatin AUC 5 IVa vs similar drugs
- Pricing: Carboplatin AUC 5 IVa cost, discount & access